News
Mayo Clinic's use of enhanced radio-frequency identification technology to track specimens from the clinical setting to the lab reduces the risk of errors and protects valuable — sometime irreplaceable — patient samples.
Dr. Binnicker's experience developing Mayo Clinic's first diagnostic COVID-19 test was recently featured in Mayo Clinic Alumni magazine.
Mayo Clinic and Thermo Fisher have joined forces to bring innovative solutions to patients.
Mayo Clinic Laboratories will be migrating the MayoACCESS application to the authentication service used across Mayo Clinic.
The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.
On Saturday, March 13 at 6 p.m. CT, Mayo Clinic Laboratories will be migrating to the authentication service used across Mayo Clinic.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
In February 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
A study involving Mayo Clinic investigators that examined new approaches to the diagnosis of heparin-induced thrombocytopenia has been met with enthusiasm in the scientific community.
In an article in The Globe and Mail, Matthew Binnicker, Ph.D., discussed factors that could be contributing to the recent drop in case counts.
In an article exploring the low prevalence of flu cases, Dr. Binnicker was among the experts consulted on why influenza is so scarce this year.
Jane Hermansen of Mayo Clinic Labs weighs in on a discussion of uses for expanded testing capacity after the pandemic is over.
In January, Mayo Clinic Laboratories announced a new test along with numerous reference value changes, obsolete tests, and algorithm changes.